Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(ÅKERMAN MÅNS) > (2000-2004) > Prognostic implicat...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05175naa a2200661 4500
001		oai:lup.lub.lu.se:dd3c1cf3-397d-4d51-9756-a22b261e6272
003		SwePub
008		160401s2002 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://lup.lub.lu.se/record/1070042 URI
040		a (SwePub)lu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Jerkeman, Matsu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-mje
245	1 0	a Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
264	1	c 2002
520		a The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a Gene Rearrangement B-Lymphocyte : genetics
653		a Human
653		a Immunophenotyping
653		a Lymphoma B-Cell : drug therapy : genetics
653		a Leucovorin : therapeutic use
653		a Lactate Dehydrogenase : metabolism
653		a Lymphoma Large-Cell Diffuse : drug therapy : genetics
653		a Male
653		a Methotrexate : therapeutic use
653		a Middle Age
653		a Neoplasm Staging
653		a Prednisone : therapeutic use
653		a Prognosis
653		a Proto-Oncogene Proteins : genetics
653		a Support Non-U.S. Gov't
653		a Vincristine : therapeutic use
653		a Transcription Factors : genetics
653		a Doxorubicin : therapeutic use
653		a DNA-Binding Proteins : genetics
653		a DNA Neoplasm : analysis : metabolism
653		a Cyclophosphamide : therapeutic use
653		a Blotting Southern
653		a Bleomycin : therapeutic use
653		a Antineoplastic Combined Chemotherapy Protocols : therapeutic use
653		a Aged
653		a Adolescence
653		a Adult
700	1	a Aman, P4 aut
700	1	a Cavallin-Ståhl, Evau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ecs
700	1	a Torlakovic, E4 aut
700	1	a Åkerman, Månsu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-mak
700	1	a Mitelman, Felixu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)kgen-fmi
700	1	a Fioretos, Thoasu Lund University,Lunds universitet,Avdelningen för klinisk genetik,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Genetics,Department of Laboratory Medicine,Faculty of Medicine4 aut0 (Swepub:lu)kgen-tfi
710	2	a Bröstcancer-genetikb Sektion I4 org
773	0	t International Journal of Oncologyg 20:1, s. 161-165q 20:1<161-165x 1019-6439
856	4	u http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11743658x freey FULLTEXT
856	4	u http://147.52.72.117/IJO/2002/volume20/number1/161-165.pdfx freey FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/107004

Hitta via bibliotek

International Journal of Oncology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Jerkeman, Mats; Aman, P; Cavallin-Ståhl, ...; Torlakovic, E; Åkerman, Måns; Mitelman, Felix; visa fler...; Fioretos, Thoas; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: International Jo ...

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se